BRIEF-Kelun-Biotech's Sac-TMT + Pembrolizumab Improves Survival In Late-Stage China Trial

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

May 22 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:

  • SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL-SAFETY PROFILE OF SAC-TMT + PEMBROLIZUMAB GENERALLY MANAGEABLE, CONSISTENT WITH SAFETY PROFILE OF COMPONENTS

  • SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: SACITUZUMAB TIRUMOTECAN + PEMBROLIZUMAB EXTENDED PFS VERSUS PEMBROLIZUMAB ALONE IN PHASE 3 LUNG CANCER TRIAL

  • SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL: OBJECTIVE RESPONSE RATE 70.2% WITH SAC-TMT PLUS PEMBROLIZUMAB VERSUS 42.0% WITH PEMBROLIZUMAB ALONE

Further company coverage: 6990.HK


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.